🚀 VC round data is live in beta, check it out!
Jiuzhou Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jiuzhou Pharmaceutical and similar public comparables like Sai Life Sciences, PharmaResearch, Piramal Pharma, Fagron and more.
Jiuzhou Pharmaceutical Overview
About Jiuzhou Pharmaceutical
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based pharmaceutical manufacturer. The company is primarily engaged in the manufacturing, research, development, and sale of active pharmaceutical ingredients, intermediates, asymmetric catalyst, and lithium battery materials. Its active pharmaceutical ingredient offerings include Carbamazepine, Duloxetine, Bezafibrate, Meropenem, Sulphadimethoxine Sodium, Oxcarbazepine, and Amprolium, among others. The firm also provides services of new drug contract development and manufacturing organization to the international pharmaceutical giant.
Founded
1973
HQ
Employees
4.9K
Website
Financials (LTM)
EV
$2B
Jiuzhou Pharmaceutical Financials
Jiuzhou Pharmaceutical reported last 12-month revenue of $845M and EBITDA of $238M.
In the same LTM period, Jiuzhou Pharmaceutical generated $289M in gross profit, $238M in EBITDA, and $143M in net income.
Revenue (LTM)
Jiuzhou Pharmaceutical P&L
In the most recent fiscal year, Jiuzhou Pharmaceutical reported revenue of $757M and EBITDA of $170M.
Jiuzhou Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $845M | XXX | $757M | XXX | XXX | XXX |
| Gross Profit | $289M | XXX | $256M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $238M | XXX | $170M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $143M | XXX | $89M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jiuzhou Pharmaceutical Stock Performance
Jiuzhou Pharmaceutical has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Jiuzhou Pharmaceutical's stock price is $2.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -2.2% | XXX | XXX | XXX | $0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJiuzhou Pharmaceutical Valuation Multiples
Jiuzhou Pharmaceutical trades at 2.2x EV/Revenue multiple, and 7.7x EV/EBITDA.
EV / Revenue (LTM)
Jiuzhou Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Jiuzhou Pharmaceutical has market cap of $2B and EV of $2B.
Equity research analysts estimate Jiuzhou Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiuzhou Pharmaceutical has a P/E ratio of 15.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 10.6x | XXX | 13.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | 7.2x | XXX | XXX | XXX |
| P/E | 15.5x | XXX | 25.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 122.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jiuzhou Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jiuzhou Pharmaceutical Margins & Growth Rates
Jiuzhou Pharmaceutical's revenue in the last 12 month grew by 8%.
Jiuzhou Pharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Jiuzhou Pharmaceutical's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiuzhou Pharmaceutical's rule of X is 48% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jiuzhou Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jiuzhou Pharmaceutical Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Jiuzhou Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sai Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaResearch | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiuzhou Pharmaceutical M&A Activity
Jiuzhou Pharmaceutical acquired XXX companies to date.
Last acquisition by Jiuzhou Pharmaceutical was on XXXXXXXX, XXXXX. Jiuzhou Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jiuzhou Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJiuzhou Pharmaceutical Investment Activity
Jiuzhou Pharmaceutical invested in XXX companies to date.
Jiuzhou Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Jiuzhou Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jiuzhou Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jiuzhou Pharmaceutical
| When was Jiuzhou Pharmaceutical founded? | Jiuzhou Pharmaceutical was founded in 1973. |
| Where is Jiuzhou Pharmaceutical headquartered? | Jiuzhou Pharmaceutical is headquartered in China. |
| How many employees does Jiuzhou Pharmaceutical have? | As of today, Jiuzhou Pharmaceutical has over 4K employees. |
| Is Jiuzhou Pharmaceutical publicly listed? | Yes, Jiuzhou Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical trades under 603456 ticker. |
| When did Jiuzhou Pharmaceutical go public? | Jiuzhou Pharmaceutical went public in 2014. |
| Who are competitors of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical main competitors are Sai Life Sciences, PharmaResearch, Piramal Pharma, Fagron. |
| What is the current market cap of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's current market cap is $2B. |
| What is the current revenue of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12 months revenue is $845M. |
| What is the current revenue growth of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Jiuzhou Pharmaceutical? | Current revenue multiple of Jiuzhou Pharmaceutical is 2.2x. |
| Is Jiuzhou Pharmaceutical profitable? | Yes, Jiuzhou Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiuzhou Pharmaceutical? | Jiuzhou Pharmaceutical's last 12 months EBITDA is $238M. |
| What is Jiuzhou Pharmaceutical's EBITDA margin? | Jiuzhou Pharmaceutical's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Jiuzhou Pharmaceutical? | Current EBITDA multiple of Jiuzhou Pharmaceutical is 7.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.